MYF6 and B-cell chronic lymphocytic leukemia: Rates of MYF6 expression were lower for other hematologic malignancies, including 92% for IGHV4-34+ HCL, 32% for IGHV4-34-negative HCLv, 41% for IGHV4-34+ HCLv, 73% for CLL, 60% for marginal zone lymphoma (MZL) and 8% for mantle cell lymphoma (MCL).